Embody vs SnagRx 2026: Both $69/mo — Which $69 Is Actually Better?

The 10-second verdict

Same $69/$119 headline, different deal underneath. SnagRx wins for most buyers — its rate is locked for life (never rises at renewal or higher doses) and its plan is structured as a monthly-billed commitment rather than an $828–$1,428 non-refundable lump sum. Embody wins only on month-to-month — $79/$129 vs SnagRx's $99/$149 — which matters if you refuse any commitment at all.

Head-to-head, September 2026

The three differences that actually matter

1. Locked-for-life vs buy-again pricing

SnagRx's signature feature: the $69/$119 rate you lock on day one stays yours at renewal, forever, at any dose. Embody's $69 is the price of this year's prepay — when your 12 months end, you rebuy at whatever rate exists then. Over two years that distinction can matter more than the starting number, especially if compounded pricing rises when the FDA shortage list changes.

2. Upfront cash vs plan structure

Embody's best rate requires $828 (sema) or $1,428 (tirz) paid at once — and it's non-refundable after shipment. SnagRx's 12-month plan reaches the same rate without the lump sum. If you stop at month 4, Embody keeps the remaining months; the structure of SnagRx's plan is kinder to early exits — confirm its exact cancellation policy before committing.

3. Transparency on pharmacies

SnagRx names its four 503A dispensing pharmacies publicly and holds LegitScript certification. Embody routes through a partner network without naming them on public pages. Both prescribe via OpenLoop — same clinician network, different disclosure culture.

Where Embody actually wins

• Pure month-to-month: $79/$129 is the cheapest no-commitment rate in class — $20/mo under SnagRx's $99/$149
• Track record: larger patient base and longer operating history, which matters when your supply chain depends on the company still existing in month 10
• Flexibility: easy to try for 1-2 months before deciding on any prepay

The smart sequencing play

Because compounded GLP-1 supply depends on the FDA shortage list — and either company could reprice or exit mid-year — the lowest-risk path is: start Embody month-to-month at $79 (cheapest entry, no lock-in), confirm tolerability and shipping reliability for 60–90 days, then switch to SnagRx's 12-month plan to lock $69/$119 for life. You pay ~$30 more for the trial quarter and end up with the best long-term contract.

Bottom line

At the headline they're a coin flip — but the contracts aren't the same product. SnagRx's lifetime lock and named-pharmacy transparency make it the better 12-month commitment; Embody's cheaper month-to-month makes it the better trial. Either way, both beat the $145/mo market median by half.

Affiliate disclosure: This article contains affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. Compounded GLP-1 medications are not FDA-approved as finished products and require a prescription. Pricing verified September 2026 — confirm current rates at checkout.